© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Surmodics, Inc. (SRDX) stock surged +0.35%, trading at $42.98 on NASDAQ, up from the previous close of $42.98. The stock opened at $42.98, fluctuating between $42.98 and $42.98 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 18, 2025 | 42.87 | 43.00 | 41.85 | 42.98 | 5.32M |
| Nov 17, 2025 | 42.82 | 42.89 | 42.80 | 42.83 | 8.99M |
| Nov 14, 2025 | 41.36 | 41.73 | 41.36 | 41.61 | 442.61K |
| Nov 13, 2025 | 41.41 | 41.63 | 41.32 | 41.41 | 515.07K |
| Nov 12, 2025 | 40.96 | 41.66 | 40.94 | 41.35 | 732.01K |
| Nov 11, 2025 | 41.05 | 41.20 | 40.63 | 40.94 | 2.7M |
| Nov 10, 2025 | 26.92 | 27.96 | 26.00 | 27.34 | 138.29K |
| Nov 07, 2025 | 26.28 | 27.26 | 26.10 | 26.79 | 153.26K |
| Nov 06, 2025 | 27.44 | 27.44 | 25.90 | 26.42 | 112.57K |
| Nov 05, 2025 | 27.70 | 27.77 | 25.87 | 27.55 | 115.7K |
| Nov 04, 2025 | 28.05 | 28.12 | 27.40 | 27.50 | 103.42K |
| Nov 03, 2025 | 27.59 | 28.67 | 27.40 | 28.32 | 117.05K |
| Oct 31, 2025 | 27.15 | 27.50 | 27.10 | 27.44 | 124.97K |
| Oct 30, 2025 | 26.90 | 27.81 | 26.75 | 27.17 | 78.15K |
| Oct 29, 2025 | 27.35 | 27.84 | 26.73 | 26.93 | 81.75K |
| Oct 28, 2025 | 27.40 | 27.53 | 27.25 | 27.36 | 55.89K |
| Oct 27, 2025 | 27.26 | 27.50 | 27.05 | 27.46 | 83.74K |
| Oct 24, 2025 | 27.65 | 27.65 | 27.09 | 27.26 | 44.02K |
| Oct 23, 2025 | 28.12 | 28.12 | 26.77 | 27.50 | 113.67K |
| Oct 22, 2025 | 28.25 | 28.46 | 27.89 | 28.28 | 105.39K |
Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as design, development, and manufacturing of interventional medical devices, primarily balloons and catheters, including drug-coated balloons for peripheral arterial disease treatment and other applications. The IVD segment designs, develops, and manufactures component products and technologies for diagnostic immunoassay, as well as molecular test and biomedical research applications. This segment offers protein stabilization reagents, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
| Employees | 389 |
| Beta | 1.39 |
| Sales or Revenue | $126.08M |
| 5Y Sales Change% | 0.523% |
| Fiscal Year Ends | September |
| Sector | Healthcare |
| Industry | Medical - Devices |